Evidence map›Paper›PMID 27302486›Full record

ArticleCellular microbiology2016

Characterization of V. cholerae T3SS-dependent cytotoxicity in cultured intestinal epithelial cells.

Kelly A Miller, Mudit Chaand, Stacy Gregoire, Takeshi Yoshida, Lisa A Beck, Andrei I Ivanov, Michelle Dziejman

Open access · bronzeAbstract read
In one paragraph

Article in Cellular microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. VopX, a novelmBio · 2025
    Article
  2. Non-O1/Non-O139Microorganisms · 2024
    Review
  3. Article
  4. Article
  5. Virulence Regulation and Innate Host Response in the Pathogenicity ofFrontiers in cellular and infection microbiology · 2020
    Review
  6. Vibrio variations on a type three theme.Current opinion in microbiology · 2019
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kelly A MillerDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Mudit ChaandDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Stacy GregoireDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Takeshi YoshidaDepartment of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Lisa A BeckDepartment of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Andrei I IvanovGastroenterology and Hepatology Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Michelle DziejmanDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
University of Rochester · US

Funding

Training in Microbial PathogenesisT32AI007362 · NIAID · UNIVERSITY OF ROCHESTER · PI IGLEWSKI, BARBARA H. · 1990 to 2010
$2.6M
Pathogenic mechanisms of non-01/non-0139 V. choleraeR01AI073785 · NIAID · UNIVERSITY OF ROCHESTER · PI DZIEJMAN, MICHELLE · 2008 to 2012
$1.9M
Junctional exocytosis and breakdown of the intestinal barrier in inflammationR01DK083968 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI IVANOV, ANDREI IVANOVICH · 2010 to 2014
$1.6M
Actin dynamics and regulation of epithelial barrier in intestinal inflammationR01DK084953 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI IVANOV, ANDREI IVANOVICH · 2010 to 2013
$1.3M
Effect of the PPAR Agonist Pioglitazone on Epidermal Barrier in Atopic DermatitisR21AR062357 · NIAMS · UNIVERSITY OF ROCHESTER · PI BECK, LISA ANN · 2012 to 2014
$380k
NIAID NIH HHS R01 AI073785NIAID NIH HHS T32 AI007362NIAMS NIH HHS R21 AR062357NIDDK NIH HHS R01 DK083968NIDDK NIH HHS R01 DK084953
6 · The paper itself

Abstract

AM-19226 is a pathogenic, non-O1/non-O139 serogroup strain of Vibrio cholerae that uses a Type 3 Secretion System (T3SS) mediated mechanism to colonize host tissues and disrupt homeostasis, causing cholera. Co-culturing the Caco2-BBE human intestinal epithelial cell line with AM-19226 in the presence of bile results in rapid mammalian cell death that requires a functional T3SS. We examined the role of bile, sought to identify the mechanism, and evaluated the contributions of T3SS translocated effectors in in vitro cell death. Our results suggest that Caco2-BBE cytotoxicity does not proceed by apoptotic or necrotic mechanisms, but rather displays characteristics consistent with osmotic lysis. Cell death was preceded by disassembly of epithelial junctions and reorganization of the cortical membrane skeleton, although neither cell death nor cell-cell disruption required VopM or VopF, two effectors known to alter actin dynamics. Using deletion strains, we identified a subset of AM-19226 Vops that are required for host cell death, which were previously assigned roles in protein translocation and colonization, suggesting that they function other than to promote cytotoxicity. The collective results therefore suggest that cooperative Vop activities are required to achieve cytotoxicity in vitro, or alternatively, that translocon pores destabilize the membrane in a bile dependent manner.

Indexed as

Gene Expression Regulation, BacterialHost-Pathogen InteractionsBacterial ProteinsBileBile Acids and SaltsCaco-2 CellsCell DeathGene DeletionHumansOsmotic PressureSignal TransductionType III Secretion SystemsVibrio choleraeVirulenceBacterial ProteinsBile Acids and SaltsType III Secretion Systems

Identifiers

PMID27302486
PMCPMC5118105
OpenAlexW2423105337

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.